Laurence Robertson – 2015 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Laurence Robertson on 2015-10-26.

To ask the Secretary of State for Health, what recent assessment he has made of the effectiveness of the (a) Bendamustine and (b) Ibrutinib drugs in treating cancer; and if he will make a statement.

George Freeman

The National Institute for Health and Care Excellence (NICE) is the independent body which makes decisions on the clinical and cost effectiveness of products based on a thorough assessment of the best available evidence and in consultation with stakeholders. National Health Service commissioners are required to fund drugs and treatments recommended by NICE technology appraisals.

Bendamustine (Levact) is recommended by NICE as a possible treatment for some people with chronic lymphocytic leukaemia of Binet stage B or C.

NICE is currently appraising ibrutinib (Imbruvica) for the treatment of (i) chronic lymphocytic leukaemia (NICE’s final guidance is expected in June 2016) and (ii) mantle cell, relapsed, refractory lymphoma (NICE’s final guidance is expected in December 2016).